



MEDICAL TIPS

AZIBEST TABLETS

Issue VIII, No. 32, 2022

Azithromycin oral suspension in prevention and management of oral mucositis in patients undergoing hematopoietic stem cell transplantation: a randomized controlled trial

S. Parkhideh et.al; Support Care Cancer. 2022 Jan;30(1):251-257.

- A single-blind, randomized controlled trial was conducted to investigate the effects of azithromycin suspension on Oral Mucositis (OM) in patients undergoing hematopoietic stem cell transplantation (HSCT).
- Azithromycin suspension was administered twice daily by gargling for 30 seconds and swallowing, on the first day of chemotherapy for patients in the intervention group.
- The incidence and duration of the mucositis improved significantly with Azithromycin suspension.
- Use of Azithromycin was associated with a decreased incidence of dryness (P 0.001), dysphagia (P 0.001), & taste loss (P 0.001). In the intervention group, mucositis-related discomfort was also reported to be less severe (P = 0.01) and lasted less time (p = 0.045).

As there were no notable adverse medication reactions reported in individuals taking azithromycin, azithromycin suspension is a useful alternative in the prevention and treatment of chemotherapy-induced oral mucositis (OM).

